- 新诊断多发性骨髓瘤患者120例临床分析
- 作者:王茂生|发布时间:2010-12-25|浏览量:895次
廊坊市中医医院 中国中医血液专病医疗中心
李君 杨淑莲 王茂生 韩二英
【摘要】目的:回顾性分析多发性骨髓瘤(MM)的临床特征,总结各治疗方案疗效。方法:回顾性分析120例新诊断MM患者的临床首发症状、实验室检查资料、治疗方法以MP、M2、VAD、BD、Thal+DEX等方案化疗为主的临床疗效。结果:120例MM患者,发病高峰在40~60岁,平均发病年龄54岁,发病年龄在国内有年轻化趋势;MM首发症状以骨骼疼痛、贫血、感染最为常见;临床疗效:(1)MP方案和M2方案临床疗效比较,x2=2.439,P>0.05,两组无显著性差异;MP方案和VAD方案临床疗效比较,x2=10.626, P<0.05, 两组具显著性差异;MP方案和Thal+DEX方案临床疗效比较,x2=5.870, P>0.05,两组无显著性差异。(2)M2方案与VAD方案临床疗效比较,x2=8.307, P<0.05, 两组具显著性差异;M2方案和Thal+DEX方案临床疗效比较,x2=2.592, P>0.05,两组无显著性差异。(3)VAD和Thal+DEX方案临床疗效比较,x2=0.916, P>0.05,两组无显著性差异。(4)BD方案总有效率最高,但由于观察例数尚少,尚需进一步观察。结论:目前国内MM治疗仍以化疗为主,主要方案MP、M2、VAD、BD等,均有一定的疗效,适合不同的患者群休。但MM患者的疗效有待进一步提高。适宜化疗方案的选择并联合自体或异基因造血干细胞移植将有助于改善该疾病患者的预后。廊坊市中医院血液科王茂生
【关键词】多发性骨髓瘤 诊断 临床特征 治疗
[Abstract] Objective:A retrospective analysis of multiple myeloma (MM) of the clinical features, summarize the treatment effect. Methods: A retrospective analysis of 120 patients with newly diagnosed multiple myeloma clinical initial symptoms, laboratory data, treatment with MP, M2, VAD, BD, Thal + DEX and other chemotherapy based clinical efficacy. Results: 120 cases of MM patients, the peak incidence in 40-60 years, average age 54 years, age at home are getting younger and younger; MM initial symptoms to bone pain, anemia, infection most common; Clinical efficacy: (1) MP programs and clinical effects of the program M2, x2 = 2.439, P> 0.05, no significant difference between the two groups; MP programs and clinical effects of VAD program, x2 = 10.626, P <0.05, two groups with significant difference; MP programs and Thal + DEX clinical effects of the program, x2 = 5.870, P> 0.05, no significant difference between the two groups. (2) M2 programs and VAD, clinical effects, x2 = 8.307, P <0.05, two significant differences; M2 programs and Thal + DEX program clinical effects, x2 = 2.592, P> 0.05, there was no significant difference . (3) VAD and Thal + DEX clinical effects of the program, x2 = 0.916, P> 0.05, no significant difference between the two groups. (4) BD program there is always the most efficient, but because of the number of observed cases was small, needs further observation. Conclusion: At present, treatment is chemotherapy, and MM, the main scheme MP, M2, VAD, BD, etc., have a certain effect, for different patient groups off. However, the efficacy of MM patients to be further improved. The choice of appropriate chemotherapy and autologous or allogeneic hematopoietic stem cell transplantation will help to improve the prognosis of the disease.